neotame: structure in first source
neotame : A dipeptide composed of N-(3,3-dimethylbutyl)-L-aspartic acid and methyl L-phenylalanate units joined by a peptide linkage.
ID Source | ID |
---|---|
PubMed CID | 9810996 |
CHEMBL ID | 3718532 |
CHEBI ID | 83503 |
SCHEMBL ID | 4311 |
MeSH ID | M0357909 |
Synonym |
---|
neotame [nf] |
hsdb 7965 |
l-phenylalanine, n-(3,3-dimethylbutyl)-l-alpha-aspartyl-, 2-methyl ester |
unii-vj597d52ex |
vj597d52ex , |
neotame |
n-(n-(3,3-dimethylbutyl)-l-alpha-aspartyl)-l-phenylalanine 1-methyl ester |
nc 00723 |
(3s)-4-[[(1s)-1-benzyl-2-methoxy-2-oxo-ethyl]amino]-3-(3,3-dimethylbutylamino)-4-oxo-butanoic acid |
165450-17-9 |
A810640 |
(s)-3-((3,3-dimethylbutyl)amino)-4-(((s)-1-methoxy-1-oxo-3-phenylpropan-2-yl)amino)-4-oxobutanoic ac |
S4442 |
BCP9000982 |
(s)-3-((3,3-dimethylbutyl)amino)-4-(((s)-1-methoxy-1-oxo-3-phenylpropan-2-yl)amino)-4-oxobutanoic acid |
BCP0726000005 |
AM84564 |
(3s)-3-[(3,3-dimethylbutyl)amino]-3-{[(2s)-1-methoxy-1-oxo-3-phenylpropan-2-yl]carbamoyl}propanoic acid |
neotame [mi] |
neotame [mart.] |
nc-00723 |
n-(n-(3,3-dimethylbutyl)-l-.alpha.-aspartyl)-l-phenylalanine 1-methyl ester |
mirasee 200 |
neotame [fhfi] |
l-phenylalanine, n-(n-(3,3-dimethylbutyl)-l-.alpha.-aspartyl)-1-methyl ester |
e 961 |
neotame [fcc] |
ins-961 |
ins no.961 |
neotame [ii] |
neotame [usp-rs] |
e-961 |
neotame [inci] |
SCHEMBL4311 |
methyl n-(3,3-dimethylbutyl)-l-alpha-aspartyl-l-phenylalaninate |
n-[n-(3,3-dimethylbutyl)-l-alpha-aspartyl]-l-phenylalanine methyl ester |
CHEBI:83503 |
DTXSID50167950 |
CHEMBL3718532 |
GS-3213 |
neotame, analytical standard |
J-010204 |
(3s)-3-(3,3-dimethylbutylamino)-4-[[(2s)-1-methoxy-1-oxo-3-phenylpropan-2-yl]amino]-4-oxobutanoic acid |
CS-W011769 |
Q415698 |
HLIAVLHNDJUHFG-HOTGVXAUSA-N |
AKOS016842430 |
HY-W011053 |
(s)-3-((3,3-dimethylbutyl)amino)-4-(((s)-1-methoxy-1-oxo-3-phenylpropan-2-yl)amino)-4-oxobutanoicacid |
neotame 1000 microg/ml in water |
N1112 |
Neotame (NEO) is a new artificial sweetener approved as a food additive in many countries. Neotame is a relatively new low-caloric and high-intensity artificialSweetener.
Excerpt | Reference | Relevance |
---|---|---|
"Neotame is a relatively new low-caloric and high-intensity artificial sweetener, approved by FDA in 2002." | ( Effects of the Artificial Sweetener Neotame on the Gut Microbiome and Fecal Metabolites in Mice. Bian, X; Chi, L; Gao, B; Lai, Y; Lu, K; Ru, H; Tu, P, 2018) | 1.48 |
"Neotame (NEO) is a new artificial sweetener approved as a food additive in many countries. " | ( Determination of neotame in non-alcoholic beverage by capillary zone electrophoresis. Gao, Y; Hu, F; Liu, H; Luan, F; Xu, L, 2013) | 2.17 |
Excerpt | Reference | Relevance |
---|---|---|
" In definitive safety studies, there were no adverse findings related to neotame treatment from clinical observations, physical examinations, water consumption, or clinical pathology evaluations; nor was there morbidity, mortality, organ toxicity, macroscopic or microscopic postmortem findings." | ( Food consumption and body weight changes with neotame, a new sweetener with intense taste: differentiating effects of palatability from toxicity in dietary safety studies. Comer, CP; Mayhew, DA; Stargel, WW, 2003) | 0.81 |
" This study investigates the question of whether the changes in BWG were adverse or secondary to small, long-term decrements in FC." | ( Long-term food consumption and body weight changes in neotame safety studies are consistent with the allometric relationship observed for other sweeteners and during dietary restrictions. Blackburn, GL; Comer, CP; Flamm, WG; Mayhew, DA; Stargel, WW, 2003) | 0.57 |
Excerpt | Relevance | Reference |
---|---|---|
" Concentrations were increased as animals grew to maintain constant dosing on a "mg/kg bw/day" basis." | ( Food consumption and body weight changes with neotame, a new sweetener with intense taste: differentiating effects of palatability from toxicity in dietary safety studies. Comer, CP; Mayhew, DA; Stargel, WW, 2003) | 0.58 |
" Altogether, our findings indicate that denatonium stimulates CASR by shifting a dose-response curve for the principal CASR agonist Ca(2+) to lower concentrations." | ( Stimulation of the extracellular Ca²⁺-sensing receptor by denatonium. Bystrova, MF; Churbanov, GD; Kolesnikov, SS; Rogachevskaja, OA; Romanov, RA, 2011) | 0.37 |
Role | Description |
---|---|
environmental contaminant | Any minor or unwanted substance introduced into the environment that can have undesired effects. |
xenobiotic | A xenobiotic (Greek, xenos "foreign"; bios "life") is a compound that is foreign to a living organism. Principal xenobiotics include: drugs, carcinogens and various compounds that have been introduced into the environment by artificial means. |
sweetening agent | Substance that sweeten food, beverages, medications, etc. |
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Class | Description |
---|---|
dipeptide | Any molecule that contains two amino-acid residues connected by peptide linkages. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (3.13) | 18.2507 |
2000's | 15 (46.88) | 29.6817 |
2010's | 12 (37.50) | 24.3611 |
2020's | 4 (12.50) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (58.22) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 1 (3.03%) | 5.53% |
Reviews | 3 (9.09%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 29 (87.88%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |